NACDS Statement on FDA’s Recommendation to Reschedule Hydrocodone

Published Online: Friday, October 25, 2013
Follow Pharmacy_Times:
PRESS RELEASE

Arlington, Va. - NACDS issued the following statement on October 24 regarding news that the Food and Drug Administration (FDA) is recommending the rescheduling of combination hydrocodone medications from Schedule III to Schedule II:

“Pharmacies have a zero tolerance for prescription drug abuse and a 100-percent commitment to patient care. This proposal is not the best avenue to address abuse, and would negatively impact access to needed medications for those who suffer from chronic pain. In the interest of patient care, we have worked with patient advocacy groups in opposition to this recommendation as we support and advance workable solutions.”

For more information, please see a recent column by NACDS President and CEO Steven C. Anderson, IOM, CAE, titled “Addressing Prescription Drug Abuse and Access Issues – Every Day.”
Related Articles
Drugs that contain hydrocodone will be moved to a more restrictive category of the Controlled Substances Act.
Aspirin not only prevents the production of pain-causing compounds in the body, but also triggers an enzyme to speed the reduction of inflammation.
Galleon Pharmaceuticals Corp's GAL-021 reverses and prevents respiratory depression associated with opioid use without affecting analgesia.
The Drug Enforcement Administration has officially placed tramadol, a centrally acting opioid analgesic, into schedule IV of the Controlled Substances Act.
Latest Issues
$auto_registration$